Boon Adam, Barnett Elizabeth, Culliford Lucy, Evans Rebecca, Frost Jessica, Hansen-Kaku Zastra, Hollingworth William, Johnson Emma, Judge Andrew, Marques Elsa M R, Metcalfe Andrew, Navvuga Patricia, Petrie Michael J, Pike Katie, Wylde Vikki, Whitehouse Michael R, Blom Ashley W, Matharu Gulraj S
Bristol Trials Centre, University of Bristol Faculty of Health Sciences, Bristol, UK.
Southmead Hospital,, North Bristol NHS Trust, Westbury-on-Trym, Bristol, UK.
Bone Jt Open. 2024 Jun 3;5(6):464-478. doi: 10.1302/2633-1462.56.BJO-2023-0154.
During total knee replacement (TKR), surgeons can choose whether or not to resurface the patella, with advantages and disadvantages of each approach. Recently, the National Institute for Health and Care Excellence (NICE) recommended always resurfacing the patella, rather than never doing so. NICE found insufficient evidence on selective resurfacing (surgeon's decision based on intraoperative findings and symptoms) to make recommendations. If effective, selective resurfacing could result in optimal individualized patient care. This protocol describes a randomized controlled trial to evaluate the clinical and cost-effectiveness of primary TKR with always patellar resurfacing compared to selective patellar resurfacing.
The PAtellar Resurfacing Trial (PART) is a patient- and assessor-blinded multicentre, pragmatic parallel two-arm randomized superiority trial of adults undergoing elective primary TKR for primary osteoarthritis at NHS hospitals in England, with an embedded internal pilot phase (ISRCTN 33276681). Participants will be randomly allocated intraoperatively on a 1:1 basis (stratified by centre and implant type (cruciate-retaining vs cruciate-sacrificing)) to always resurface or selectively resurface the patella, once the surgeon has confirmed sufficient patellar thickness for resurfacing and that constrained implants are not required. The primary analysis will compare the Oxford Knee Score (OKS) one year after surgery. Secondary outcomes include patient-reported outcome measures at three months, six months, and one year (Knee injury and Osteoarthritis Outcome Score, OKS, EuroQol five-dimension five-level questionnaire, patient satisfaction, postoperative complications, need for further surgery, resource use, and costs). Cost-effectiveness will be measured for the lifetime of the patient. Overall, 530 patients will be recruited to obtain 90% power to detect a four-point difference in OKS between the groups one year after surgery, assuming up to 40% resurfacing in the selective group.
The trial findings will provide evidence about the clinical and cost-effectiveness of always patellar resurfacing compared to selective patellar resurfacing. This will inform future NICE guidelines on primary TKR and the role of selective patellar resurfacing.
在全膝关节置换术(TKR)过程中,外科医生可以选择是否对髌骨进行表面置换,每种方法都有其优缺点。最近,英国国家卫生与临床优化研究所(NICE)建议始终对髌骨进行表面置换,而不是从不这样做。NICE发现关于选择性表面置换(外科医生根据术中发现和症状做出决定)的证据不足,无法给出建议。如果有效,选择性表面置换可以实现最佳的个体化患者护理。本方案描述了一项随机对照试验,以评估与选择性髌骨表面置换相比,始终进行髌骨表面置换的初次TKR的临床和成本效益。
髌骨表面置换试验(PART)是一项患者和评估者双盲的多中心、实用平行双臂随机优效性试验,针对英格兰国民保健服务(NHS)医院中因原发性骨关节炎接受择期初次TKR的成年人,设有嵌入式内部试点阶段(ISRCTN 33276681)。一旦外科医生确认髌骨厚度足以进行表面置换且不需要限制性植入物,参与者将在术中以1:1的比例随机分配(按中心和植入物类型分层:保留交叉韧带型与牺牲交叉韧带型),以始终对髌骨进行表面置换或选择性地对髌骨进行表面置换。主要分析将比较术后一年的牛津膝关节评分(OKS)。次要结局包括术后三个月、六个月和一年的患者报告结局指标(膝关节损伤和骨关节炎结局评分、OKS、欧洲五维度五水平问卷、患者满意度、术后并发症、进一步手术需求、资源使用和成本)。将对患者的终身成本效益进行评估。总体而言,将招募530名患者,假设选择性组的表面置换率高达40%,以获得90%的检验效能,检测术后一年两组之间OKS有4分的差异。
试验结果将提供证据,说明与选择性髌骨表面置换相比,始终进行髌骨表面置换的临床和成本效益。这将为NICE未来关于初次TKR的指南以及选择性髌骨表面置换的作用提供参考。